Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

NCT04233372 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

399

Enrollment

OTHER

Sponsor class

Conditions

Hiv

Interventions

DRUG: Delstrigo

Sponsor

Hospital Clinic of Barcelona